RNAseq of CONTROL engineered and SMAD4 engineered Purified NK cells after 7 day treatment in the presence/absence of TGFb

TGF-β is a suppressive factor curtailing the effectiveness of NK cell adoptive transfer for cancer treatment. Inspired by data of SMAD4 haploinsufficient NK cells, we explored the possibility of knocking out SMAD4 by CRISPR/Cas9 in human NK cells as a novel strategy for circumventing TGF-β suppression. Human SMAD4KO NK cells were resistant to TGF-β inhibition, retaining their anti-tumor function and their proliferation in response to IL-2/IL-15. In addition, SMAD4KO NK cells exposed to TGF-β showed improved tumor-penetration, associated to changes in adhesion molecules and chemokine receptors. Indeed, the cytotoxic activity of SMAD4KO NK cells surpassed that of control NK cells treated with a TGF-β inhibitor, indirectly evidencing the advantage of maintaining SMAD4-independent TGF-β-signaling. Furthermore, SMAD4KO NK cells were also resistant to Activin A inhibition. Overall, disrupting TGF-β/activin A signaling by inactivating SMAD4 represents a promising strategy for simultaneously enhancing the homing and function of NK cell products for cancer immunotherapy. Control and SMAD4 knock out human NK cells were cultured with rIL-2 (200 U/ml) or the combination of rIL-2 and TGFbeta (5 ng/ml). After 5 days, total RNA was extracted and sequenced. The experiment contain data from NK cells obtained from 3 different healthy individuals.